Humira Competition Dominates AbbVie Earnings
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Amgen Inc. appears to have a smooth path to FDA approval of its biosimilar of AbbVie Inc.'s tumor necrosis factor Humira (adalimumab) based on documents released ahead of a July 12 advisory committee meeting. But don't expect AbbVie to just sit back and take it.
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Amgen Inc. appears to have a smooth path to FDA approval of its biosimilar of AbbVie Inc.'s tumor necrosis factor Humira (adalimumab) based on documents released ahead of a July 12 advisory committee meeting. But don't expect AbbVie to just sit back and take it.
AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout
As part of its strategy to offset the coming Humira patent cliff, AbbVie Inc. is looking to oncology as a "significant pillar of growth" going forward, a gambit CEO Richard Gonzalez says will benefit greatly from both the pipeline candidates and the solid tumor R&D engine his company will obtain in the $5.8bn purchase of Stemcentrx announced April 28.